Danaher's Beckman "back on track" as FDA re-approves troponin test
This article was originally published in Clinica
Executive Summary
Danaher’s Beckman Coulter subsidiary is set to “regain its competitive footing in the US market” after the FDA granted 510(k) clearance to its “key” Access AccuTnI+3 troponin assay for use on the UniCel Dxl system.